Revolution Medicines Stock Price, News & Analysis (NASDAQ:RVMD) $24.70 +0.73 (+3.05%) (As of 02:51 PM ET) Add Compare Share Share Today's Range$23.82▼$24.8250-Day Range$18.35▼$34.1252-Week Range$15.44▼$35.60Volume776,799 shsAverage Volume1.47 million shsMarket Capitalization$2.71 billionP/E RatioN/ADividend YieldN/APrice Target$35.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside45.2% Upside$35.50 Price TargetShort InterestBearish14.83% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$1.81 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.48) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector372nd out of 958 stocksBiotechnology Industry24th out of 75 stocks 4.4 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.50, Revolution Medicines has a forecasted upside of 45.2% from its current price of $24.45.Amount of Analyst CoverageRevolution Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.83% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Revolution Medicines has recently increased by 14.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Revolution Medicines this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,178.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Revolution Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($3.48) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesDecember 1, 2023 | americanbankingnews.comHead-To-Head Survey: Revolution Medicines (NASDAQ:RVMD) & Clarus Therapeutics (OTCMKTS:CRXTQ)November 29, 2023 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by BrokeragesDecember 7, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 24, 2023 | benzinga.comRevolution Medicines Stock (NASDAQ:RVMD) Dividends: History, Yield and DatesNovember 17, 2023 | finance.yahoo.comA great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who own 74% must be happyNovember 16, 2023 | msn.comRaymond James starts coverage of Revolution Medicines at outperformNovember 16, 2023 | markets.businessinsider.comCancer Player Revolution Medicines Gets Bullish Rating: Here's DetailsNovember 10, 2023 | seekingalpha.comRevolution Medicines: A March Halted By 'Lackluster' ESMO ReadoutDecember 7, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.November 8, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Myriad Genetics (MYGN), Revolution Medicines (RVMD) and Demant (OtherWILLF)November 8, 2023 | finance.yahoo.comRevolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNovember 7, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Revolution MedicinesNovember 7, 2023 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | seekingalpha.comRevolution Medicines, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 6, 2023 | seekingalpha.comRevolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call TranscriptNovember 6, 2023 | finance.yahoo.comRevolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate ProgressNovember 6, 2023 | finance.yahoo.comRevolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate ProgressNovember 1, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.October 31, 2023 | finance.yahoo.comRevolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023October 26, 2023 | markets.businessinsider.comPromising Phase 1 Results and Future Potential Drive Buy Rating for Revolution MedicinesOctober 26, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Revolution Medicines (RVMD)October 25, 2023 | markets.businessinsider.comRevolution Medicines Earns Buy Rating Based on Promising Phase I Data and Strong RAS Pathway Development ProspectsOctober 24, 2023 | msn.comOppenheimer Maintains Revolution Medicines (RVMD) Outperform RecommendationOctober 23, 2023 | finance.yahoo.comRebel's Edge - October 20: $TGH, $RVMD, and Astros VS RangersOctober 23, 2023 | finance.yahoo.comRevolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.October 23, 2023 | benzinga.comRevolution Medicines Stock (NASDAQ:RVMD), Analyst Ratings, Price Targets, PredictionsOctober 23, 2023 | finance.yahoo.comRevolution Crashes 43% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.See More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees338Year FoundedN/APrice Target and Rating Average Stock Price Target$35.50 High Stock Price Target$47.00 Low Stock Price Target$23.00 Potential Upside/Downside+48.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,710,000.00 Net Margins-1,003.36% Pretax Margin-1,281.44% Return on Equity-38.92% Return on Assets-33.61% Debt Debt-to-Equity RatioN/A Current Ratio9.64 Quick Ratio9.64 Sales & Book Value Annual Sales$35.38 million Price / Sales74.23 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.10Miscellaneous Outstanding Shares109,570,000Free Float100,252,000Market Cap$2.63 billion OptionableNot Optionable Beta1.50 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 61)CEO, President & Chairman Comp: $1.05MMr. Jack Anders (Age 46)Chief Financial Officer Comp: $544.8kMs. Margaret A. Horn J.D. (Age 60)Chief Operating Officer Comp: $775.6kDr. Stephen M. Kelsey FRC Path. (Age 62)FRCP, M.D., President of Research & Development Comp: $779kMs. Xiaolin Wang (Age 52)Executive Vice President of Clinical Development Comp: $604.1kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 42)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsSpringWorks TherapeuticsNASDAQ:SWTXCatalyst PharmaceuticalsNASDAQ:CPRXCelldex TherapeuticsNASDAQ:CLDXDisc MedicineNASDAQ:IRONMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPSold 198,905 shares on 12/7/2023Ownership: 0.039%Citigroup Inc.Sold 25,290 shares on 12/6/2023Ownership: 0.089%Wellington Management Group LLPBought 282,786 shares on 12/1/2023Ownership: 9.649%Deutsche Bank AGBought 6,378 shares on 11/24/2023Ownership: 0.048%Walleye Trading LLCBought 7,321 shares on 11/21/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions Should I buy or sell Revolution Medicines stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks. What is Revolution Medicines' stock price target for 2024? 8 Wall Street research analysts have issued twelve-month target prices for Revolution Medicines' shares. Their RVMD share price targets range from $23.00 to $47.00. On average, they expect the company's share price to reach $35.50 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts. How have RVMD shares performed in 2023? Revolution Medicines' stock was trading at $23.82 at the beginning of 2023. Since then, RVMD stock has increased by 2.6% and is now trading at $24.45. View the best growth stocks for 2023 here. When is Revolution Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our RVMD earnings forecast. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, November, 6th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.02. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.92%. During the same period in the prior year, the company earned ($0.87) EPS. What ETFs hold Revolution Medicines' stock? ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL). When did Revolution Medicines IPO? (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.65%), Column Group LLC (1.12%), Ameriprise Financial Inc. (1.11%), Northern Trust Corp (0.85%), Morgan Stanley (0.73%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RVMD) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.